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higher in Iranians (P-value: 0.039) and in patients whose
initial regimen was changed due to adverse drug reaction.
(P-value: 0.01) Conclusion: MDR-TB treatment using stan-
dardized regimen showed favorable outcome in our study,
comparing with previous studies.
doi:10.1016/j.ijid.2008.05.679
42.011
Investigations of Polymorphisms Associated with
Cytochrome P4503a5 and MDR1 in Patients with Severe
Leprosy Reactions Treated with Cyclosporin A
S.N.S. Marlowe1,∗, D.N.J. Lockwood2, D.W. Holt3, S.
Fredericks3, A. Johnston3
1 North Manchester General Hospital, Manchester, United
Kingdom
2 London School of Hygiene & Tropical Medicine, London,
United Kingdom
3 St Georges Hospital Medical School, London, United King-
dom
Background: The only treatment available for severe
leprosy Type 1 Reactions (T1R) is prednisolone but a sig-
niﬁcant number of patients do not respond to treatment.
There have been 2 case reports of successful treatment
of non-responsive T1R with cyclosporin A (CyA). This
study uses an Indian microemulsion formulation of CyA
(Panimmune) as monotherapy to treat patients with severe
T1R. Evidence is now available showing that some ethnic
groups metabolise CyA differently. Genetic differences
have also been identiﬁed in the genes responsible for CyA
metabolism (cytochrome P450) in various ethnic groups.
It is important to identify any groups that metabolize or
absorb CyA differently as this will help in deciding the
optimal dose to be used.
Aims: To identify any differences in dose requirements for
CyA treatment of severe leprosy T1Rs in the 2 racial groups
and whether these differences were related to genetic vari-
ations.
Methods: 33 Ethiopian and 12 Nepali patients with severe
T1Rs were recruited and treated with CyA at a dose of
5—10mg/kg/day; dose increases were dependent on clini-
cal improvement. Trough blood concentrations of CyA were
analysed using a Liquid Chromotography/Tandem Mass Spec-
trometry assay. Pharmacokinetic studies were carried out on
a subgroup of patients. DNA was extracted from whole blood
and samples genotyped using PCR and restriction length
polymorphism (RFLP). For CYPA5, AA, AG and GG genotypes
were identiﬁed and for MDR1, CC, CT and TT genotypes were
identiﬁed.
Results: 77% Ethiopian patients needed a higher dose
of CyA than the Nepalis to show a clinical improvement.
Patients with the TT and GG genotypes achieved a higher
Cmax and area under the curve (AUC) for CyA than those
with CC/CT or AG/AA genotypes respectively.
Conclusion: Polymorphisms in CYP3A5 and MDR1 may
explain variation in dose requirements for CyA in different
racial groups. This is important for all drugs that are hepat-
ically metabolised and in particular HAART medication.
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Background: Since the use of new adjuvants in design-
ing new vaccines against most of infectious diseases should
be improved, many candidates are recommended for mod-
ulating an immune response to an antigen. Neisseria
meningitidis serogroup B outer membrane vesicle (OMV) has
been used previously by Siadat et al (2007), as a carrier for
polysaccharide immunogens. In this study OMV used as an
adjuvant for group A meningococcal capsular polysaccha-
ride (GAMP) and was tested in Newzeland white rabbit for
bactericidal antibody activity induction.
Methods: The complex of OMV with GAMP, in no covalent
form, and control were injected intramuscularly into groups
of four rabbits with boosters on day 14 and 28 after primary
immunization. The following groups were used as control:
1.GAMP, 2.OMV and 3.normal saline. The serum samples
collected on days 0, 14, 28 and 42 and tested by comple-
ment mediated bactericidal assay against serogroup A and
B meningococci according to the world health organization
protocol.
Results: Rabbits given three dose of the complex of
serogroup B meningococcal OMV with GAMP developed high
level of serum bactericidal activity against serogroup A
meningococci after 42 days in comparison with the GAMP
and OMV control group (P < 0.005). Bactericidal titer against
serogroup B meningococci of the GAMP plus OMV complex
showed no signiﬁcant difference in comparison with the OMV
containing control (P > 0.005).
Conclusion: The results indicate that the combination of
OMV with GAMP, in non covalent form, would be able to
induce a high level of bactericidal antibody response in com-
parison with GAMP. The OMV of Neisseria meningitidis is a
potent protein carrier in the induction of immune system
but in this article the role of OMV is studied as an immune
system promotor in non-covalent form and without any con-
jugation process(as an adjuvant) in order to induce immune
response against three prevalent serogroups of Neisseria
meningitidis.
doi:10.1016/j.ijid.2008.05.681
